Frexalimab (Sanofi), a novel, investigational second-generation inhibitor of the CD40 ligand, significantly reduced disease activity in relapsing multiple sclerosis (MS) and was well tolerated in a […]

Severe COVID-19, but not mild, is associated with a significantly higher risk for psychiatric and neurologic disorders a year after infection, a new study shows. Compared […]

TOPLINE: A history of herpes simplex virus (HSV) is associated with a more than doubling of the risk for dementia in older people, results of a […]

A study spanning 20 years helps nail down the timing of biomarker changes that occur in the period between normal cognition and a diagnosis of sporadic […]